Pci Biotech Holding Asa · LSE:0JGL
Pci Biotech Holding Asa — Q3 2022 Earnings Presentation
22 slides from Pci Biotech Holding Asa's earnings presentation, Nov 23, 2022
Slide 1: PCI Biotech - Q3 2022 Interim Report Presentation
PCI Biotech - Enabling intracellular Q3 2022 Interim Report delivery Presentation November 23, 2022 Ronny Skuggedal, CEO / CFO Anders Høgset, CSO Morten Luhr, BD Manager www.pcibiotech.com
Slide 2: Q&A session through teleconference and webcast console
PCI Biotech Q&A session through teleconference and webcast console This presentation will also be presented through a teleconference, mainly facilitated for attendees intending to ask questions verbally during the Q&A session. If you plan to use this facility, please join the event 5-10 minutes prio
Slide 3: Important notice and disclaimer
PCI Biotech Important notice and disclaimer This presentation may contain certain forward-looking Factors that could cause these differences include, but are not limited to, statements and forecasts based on uncertainty, since they implementation of PCI Biotech’s strategy and its ability to further
Slide 4: Table of Contents
Table of Contents Highlights Operational review Key financials Outlook Q&A www.pcibiotech.com 4
Slide 5: Highlights Q3 2022: Corporate
Highlights Q3 2022 Corporate Reported in August that we will not conduct a company-sponsored Ph II trial with the fimaVACC technology Efforts to finance a Ph II clinical trial in head and neck cancer did not, under the current market conditions, result in a feasible way forward The decision en
Slide 6: Highlights Q3 2022: fimaNAC
Highlights Q3 2022 fimaNAC First step for the dermatology discovery project Dermatology Demonstrate fimaNAC-mediated nucleic acid delivery in a wound model Bioprocessing External feasibility experiments contracted, expected readout 1H 2023 The bioprocessing discovery project has matured Fo
Slide 7: Highlights Q3 2022: fimaVACC
Highlights Q3 2022 fimaVACC ► Exploring approaches aiming to identify novel immunotherapy treatment Intratumoural combinations immunotherapy Ph.D. candidate grant of up to NOK 2.5 million over 3 years from the Research Council of Norway www.pcibiotech.com 7
Slide 8: Highlights Q3 2022: Collaborations
Highlights Q3 2022 Collaborations In August 2022, a preclinical collaboration was initiated with Mymetics, aiming to explore technological synergies for possible enhancement of cancer therapy The collaborations with Mendus has been reviewed for progress and value. Priorities are set by both part
Slide 9: Highlights Q3 2022: fimaCHEM
Highlights Q3 2022 fimaCHEM All major study closure activities are expected to be completed by the end of the year Study results published in the EU clinical trial database Collected data insufficient to draw conclusions regarding efficacy Remaining cash effect for closure process estimated
Slide 10: Operational review
Operational review 10
Slide 11: fimaNAC: Dermatology nucleic acid delivery
Develop a platform technology for PCI-based delivery of nucleic acids fimaNAC to the body surface Topical delivery to intact skin Fimaporfin penetration to deeper skin layers Operational Intradermal delivery review – PCI strongly enhances delivery of injected Dermatology nucleic acids to skin Level
Slide 12: fimaNAC: Platform for nucleic acid delivery to skin
Platform technology for delivery of nucleic acids to skin fimaNAC fimaNAc - Excellent technological fit with dermatological diseases Chronic skin ulcers (e.g. diabetic ulcers) have large unmet medical need Operational review – Complex biology where fimaNAc can exploit the potential of nucleic
Slide 13: fimaNAC: Bioprocessing
fimaNAC Bioprocessing - Manufacturing capacity is a limiting factor to Operational treating more patients review – Markets: Bioprocessing Rapid growth Cell culture Short time to market Cell and gene therapy Cost-effective development Urgent need for novel technology Viral manufacturing fimaNAC has s
Slide 14: fimaNAC: Maximising yield for viral manufacturing
fimaNAC Maximising yield for viral manufacturing Operational review – Bioprocessing Cells in culture Gene edit and expand Harvest • Cell lines • Nucleic acids • Quantity of material • Range in quantity • Enzymes • Purity of material • Growth factors • Quality of material www.pcibiotech.com 14
Slide 15: fimaNAC: Partnership-driven prototype strategy
fimaNAC PROTOTYPES WILL BE DEVELOPED FOLLOWING A PARTNERSHIP-DRIVEN STRATEGY Operational • Pursue applications based on market need and technological fit review – • Apply fimaNAc to viral manufacturing proof-of-concept (alpha prototype) Bioprocessing Feasibility • Perform in-house • Partnerships are
Slide 16: fimaVACC: Intratumoural immunotherapy
Leveraging intratumoural immunotherapy to achieve a fimaVACC systemic anti-tumour immune response Operational review – Intratumoural immunotherapy ► Despite representing a major breakthrough in cancer treatment, a large proportion of patients do not respond properly to immune checkpoint inhibitors (
Slide 17: Research collaborations
Research collaborations Offer valuable scientific knowhow, encouraging results and intellectual property Collaborations span different classes of drugs and applications PCI Biotech continues to pursue new and value-adding collaborative opportunities 17
Slide 18: Research collaboration with Institute of Marine Research
RESEARCH COLLABORATION WITH INSTITUTE OF MARINE RESEARCH PHOTOLICE - PHOTOCHEMICAL TREATMENT OF SEA LICE ► Project introduction 2-year project fully funded by public grant, ending June 2023 Work performed by Institute of Marine Research (Havforskningsinstituttet) Evaluate if photochemical trea
Slide 19: Key financials, Outlook, Q&A
Key financials Outlook Q&A 19
Slide 20: Finance: Key financial figures
Finance ► Financial run-way estimated into 2024 RELEASE closure, estimated remaining cash effect up to NOK -3 million Organisational changes will further reduce costs, full effect in Q1 2023 Key financial Explore financing and strategic opportunities as non-clinical pipeline matures figures (f
Slide 21: Outlook
Outlook Leveraging the PCI technology platform within immunotherapy, dermatology, and bioprocessing Enabling intracellular delivery www.pcibiotech.com 21
Slide 22: PCI Biotech: For enquiries
Enabling intracellular PCI Biotech delivery For enquiries: Ronny Skuggedal, CEO / CFO Mobile phone: +47 940 05 757 E-mail: rs@pcibiotech.com www.pcibiotech.com 22